China Pharmaceutical Group submitted a new crown vaccine listing application China's 5 vaccines into the third phase of clinical stage

On November 25, it was reported that Shi Yanyi, deputy general manager of China National Pharmaceutical Group Co., Ltd., said that China National Pharmaceutical Group had submitted an application for the listing of the new crown vaccine to the State Drug Administration.
affected by this news, China National Pharmaceuticals shares hit the rise and fall board.
screenshot from Tonghuashun app it is understood that on February 1 this year, China National Pharmaceutical Group China Bio obtained the Ministry of Science and Technology's national key research and development plan "public security risk prevention and control and emergency technical equipment" key special inactivated vaccine project emergency project.
April 12 and 17, Wuhan Institute and Beijing each developed a new corona inactivated vaccine was approved clinically.
On July 22nd, China officially launched the emergency use of the new crown vaccine, and first established an immune barrier among medical personnel, epidemic prevention personnel, border inspectors and urban basic operators, and the vaccines of China Bio-Wuhan Institute and Beijing Institute of China Pharmaceutical Group have been approved for emergency use in China.
addition, it is reported that china Pharmaceutical Group's two vaccine production plants have been completed, by the end of this year, the production capacity of about 100 million doses, is expected to reach more than 1 billion doses next year.
price issue, which is more sensitive to the public than the public, has previously been reported that China National Pharmaceutical Group's vaccine may be priced at a maximum of 600 yuan.
because the two vaccines require two injections, the price of a single shot is 300 yuan.
this is probably the most expensive new crown vaccine on the list.
According to WHO statistics, so far there are more than 190 candidate new crown vaccines are being developed, and China's multi-vaccine research and development in the international first square, its Chinese medicine inactivated vaccine (Wuhan Institute and Beijing two), Concino / Military Academy adenovirus vector vaccine, Coxing ZTE inactivated vaccine and Zhifei biorecombination sub-unit vaccine and other 5 new corona vaccine developed by China has entered phase III.
research and development efforts overseas, the adenovirus vector vaccine developed jointly by Kantai Bio, AstraZeneta and Oxford University, as well as the mRNA vaccine developed by Fosun Pharma, Pfizer and BioNTech, are also in Phase III.
Concino announced on the 7th of this month that the company and the Academy of Military Sciences jointly developed the recombinant new coronavirus (adenovirus vector) International Phase III. clinical trial has been launched in Mexico, and has been vaccinated.
, Concino announced that it would provide 35 million doses of the new crown vaccine to Mexico between the end of 2020 and 2021.
It is understood that the cooperative vaccine was developed by the military academy of military medical research institute Chen Wei academician team, is the world's first into the clinical phase I vaccine, as early as June 25 by the Central Military Commission Health Bureau issued the military special needs drug approval (valid for 1 year).
price, there had been earlier online rumors that Consino's vaccine would be priced at cost.
that the rumor has not been officially confirmed, the pricing of exactly, pending follow-up reports.
inactivated vaccine developed by 1960-year-old Koxing Bio-Cosing Zhongwei is currently undergoing Phase III clinical trials in Brazil, Indonesia and other countries.
media reported that the vaccine was stopped on November 10 by Brazil's health regulator, the National Health Supervision Agency.
, the company issued a statement that it had regained authority to resume clinical trials of the new crown vaccine.
the vaccine was also approved on July 22 for emergency use of China's new crown vaccine.
mid-October, Zhejiang launched an emergency vaccination of the new crown vaccine, which is used.
From jiaxing City, Zhejiang Province, the official WeChat content, the region for emergency vaccination of the new crown vaccine by the provincial departments unified to Beijing Koxing biological levy, the vaccine price of 200 yuan / branch (bottle), vaccination 2 doses of a total of 400 yuan.
Koxing Zhongwei said it had fully started production of the new corona inactivated vaccine in August, with a production capacity of about 300 million doses per year, and could produce about 100 million doses of the new corona inactivated vaccine (including semi-finished products) by the end of this year. the new crown vaccine developed by Anhui Zhifei Long Koma Biopharmaceutical Co., Ltd., a subsidiary of
Zhifei Bio, was jointly developed by the company and the Institute of Microbiology of the Chinese Academy of Sciences, using a technical route similar to that of hepatitis B vaccine, hepatitis E vaccine and cervical cancer vaccine, and belongs to the recombined sub-unit vaccine.
the vaccine began a phase III clinical trial in Xiangtan County, Hunan Province, on November 18.
will begin Phase III clinical trials in Uzbekistan in the near future, and the vaccine is understood to have been delivered to Uzbekistan, where several Chinese experts are already in place to monitor volunteers and train Uzbek doctors.
, Indonesia, Pakistan and Ecuador will begin Phase III clinical trials.
it is understood that the company in September obtained a drug production license change, increased the reorganization of the new coronary vaccine matters, the new crown vaccine workshop put into use that month, trial production smoothly, annual output of more than 300 million doses.
as far as price is about, no information has been revealed.
integrated from Tencent.com, Economic Daily, Anhui.com, Qi News, Firestone creation